Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931148 | 0.92 | EPHX1 (0.67) | EPHX1CYP2C9TDP1ALDH1A1LMNA | |
| SCHEMBL19808634 | 0.80 | TSHR (0.53) | ALDH1A1LMNATSHREPHX2FBP1 | |
| SCHEMBL320112 | 0.79 | EPHX1 (0.85) | EPHX1MMP2MMP1ACHE | |
| SCHEMBL10119866 | 0.78 | ALDH1A1 (0.36) | CYP2C9TDP1ALDH1A1LMNAALB | |
| SCHEMBL19127225 | 0.77 | PRMT1 (0.66) | EPHX1EPHX2 | |
| SCHEMBL31522329 | 0.77 | PRMT1 (0.66) | EPHX1EPHX2 | |
| SCHEMBL30786047 | 0.77 | EPHX1 (0.90) | EPHX1EPHX2MMP2MMP1ACHE | |
| SCHEMBL21715999 | 0.76 | EPHX2 (0.50) | EPHX1ALDH1A1LMNAEPHX2FBP1 | |
| SCHEMBL17133784 | 0.75 | EPHX1 (0.95) | EPHX1EPHX2 | |
| SCHEMBL10400568 | 0.75 | EPHX1 (0.70) | EPHX1MMP2MMP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1011311-A4 | CONTROLLED GERMINATION USING INDUCIBLE PHYTATE GENE | EXSEED GENETICS L L C (US) | 2004-05-26 | — | — | EP | claimed |
| EP-1011311-A1 | CONTROLLED GERMINATION USING INDUCIBLE PHYTATE GENE | Exseed Genetics L.L.C. (US) | 2000-06-28 | — | — | EP | claimed |
| WO-1999007211-A9 | CONTROLLED GERMINATION USING INDUCIBLE PHYTATE GENE | EXSEED GENETICS L L C (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999007211-A1 | CONTROLLED GERMINATION USING INDUCIBLE PHYTATE GENE | EXSEED GENETICS, L.L.C. (US) | 1999-02-18 | — | — | WO | claimed |
| US-5608143-A | NUCLEIC ACID PROMOTER FRAGMENT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-04 | — | — | US | claimed |
| US-5364780-A | Genetic engineering with DNA and promoters | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| EP-0463056-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-02 | — | — | EP | claimed |
| WO-1990011361-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-04 | — | — | WO | claimed |
| EP-0388186-A1 | External regulation of gene expression | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-09-19 | — | — | EP | claimed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-5608143-A | NUCLEIC ACID PROMOTER FRAGMENT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-04 | — | — | US | disclosed |
| US-5364780-A | Genetic engineering with DNA and promoters | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0463056-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-02 | — | — | EP | disclosed |
| WO-1990011361-A1 | EXTERNAL REGULATION OF GENE EXPRESSION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-04 | — | — | WO | disclosed |
| EP-0388186-A1 | External regulation of gene expression | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | EPHX1 1923/4885CYP2C9 49/4885TDP1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.